Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Opko Health stock

Learn how to easily invest in Opko Health stock.

Opko Health is a diagnostics & research business based in the US. Opko Health shares (OPK) are listed on the NASDAQ and all prices are listed in US Dollars. Opko Health employs 5,767 staff and has a trailing 12-month revenue of around $1.2 billion.

How to buy Opko Health stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – OPK. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Opko Health stock price (NASDAQ: OPK)

Use our graph to track the performance of OPK stocks over time.

Opko Health shares at a glance

Information last updated 2023-01-25.
Latest market close$1.26
52-week range$1.03 - $3.78
50-day moving average $1.38
200-day moving average $2.19
Wall St. target price$4.95
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.18

Buy Opko Health stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Opko Health stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Opko Health price performance over time

Historical closes compared with the close of $1.26 from 2023-01-26

1 week (2023-01-20) -15.44%
1 month (2022-12-27) 17.76%
3 months (2022-10-27) -30.00%
6 months (2022-07-27) -48.99%
1 year (2022-01-27) -56.10%
2 years (2021-01-27) -77.34%
3 years (2020-01-27) 1.57
5 years (2018-01-26) 4.88

Opko Health financials

Revenue TTM $1.2 billion
Gross profit TTM $504.7 million
Return on assets TTM -6.59%
Return on equity TTM -18.67%
Profit margin -25.98%
Book value $2.11
Market capitalisation $1 billion

TTM: trailing 12 months

Opko Health share dividends

We're not expecting Opko Health to pay a dividend over the next 12 months.

Opko Health share price volatility

Over the last 12 months, Opko Health's shares have ranged in value from as little as $1.03 up to $3.78. A popular way to gauge a stock's volatility is its "beta".

OPK.US volatility(beta: 1.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Opko Health's is 1.6979. This would suggest that Opko Health's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Opko Health overview

OPKO Health, Inc. , a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico.

Frequently asked questions

What percentage of Opko Health is owned by insiders or institutions?
Currently 46.063% of Opko Health shares are held by insiders and 24.704% by institutions.
How many people work for Opko Health?
Latest data suggests 5,767 work at Opko Health.
When does the fiscal year end for Opko Health?
Opko Health's fiscal year ends in December.
Where is Opko Health based?
Opko Health's address is: 4400 Biscayne Boulevard, Miami, FL, United States, 33137
What is Opko Health's ISIN number?
Opko Health's international securities identification number is: US68375N1037
What is Opko Health's CUSIP number?
Opko Health's Committee on Uniform Securities Identification Procedures number is: 23282G105

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site